WuXi Biologics (Cayman) Inc. (2269.HK) stock analysis

In our weekly check, WuXi Biologics (Cayman) Inc. is graded B (A to F). Of 24 checks on debt, profit, cash flow and trend: 17 pass, warnings: 5, red flags: 2.

About WuXi Biologics (Cayman) Inc.

WuXi Biologics (Cayman) Inc. is a Healthcare company (Biotechnology) based in China, listed on HKSE as 2269.HK.

What our checks show for 2269.HK

Red flags

• The net margin fell by 10.4 points over 5 years, to 22.5%: the company keeps less of each sale as profit.
• The stock has fallen as much as 93% from a peak. Would you have held through that?

Warning signs

• Analysts expect the net margin to shrink by 0.9 points from today's 22.5%.
• The price is 32.1 times earnings (P/E): the market already pays for a lot of future growth.
• The price swings a lot: 45% annual volatility. Expect large ups and downs.
• The stock is still below its previous peak.
• Pay in shares equals 34.1% of free cash flow: it dilutes shareholders.

Strengths

• Debt is low: 0.06x equity.
• Operating cash flow is 1.3x net profit: the profit arrives as real cash.
• Analysts expect earnings per share to grow about 23.5% a year over the next years.
• Analysts expect revenue to grow about 20% a year over the next years.
• The company keeps 22.5% of its revenue as net profit.
• Free cash flow is 12.8% of revenue: cash for dividends, buybacks or growth.

Similar companies

1801.HK · VRTX · CSL.AX · REGN · MRNA · 9926.HK

Questions

What grade does WuXi Biologics (Cayman) Inc. (2269.HK) have?

In our weekly check, WuXi Biologics (Cayman) Inc. is graded B (A to F). Of 24 checks on debt, profit, cash flow and trend: 17 pass, warnings: 5, red flags: 2. The grade is a risk check, not a buy or sell recommendation.

What are the main risks of 2269.HK stock?

This week's biggest flags for WuXi Biologics (Cayman) Inc.: Margins falling, Deep past fall, Margins expected to shrink. In total 7 of 24 checks show a warning or a red flag.

What does WuXi Biologics (Cayman) Inc. do?

WuXi Biologics (Cayman) Inc. is a Healthcare company (Biotechnology) based in China, listed on HKSE as 2269.HK.

The grade is a risk check, not a price forecast, and not investment advice. In our 10-year test (S&P 500, 2016-2026), stocks we graded A or B fell more than 30% 2-3 times less often than D or F, without a lower average return.

Updated 2026-10-24

Open the full analysis